0001641489-23-000024.txt : 20230608 0001641489-23-000024.hdr.sgml : 20230608 20230608162434 ACCESSION NUMBER: 0001641489-23-000024 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230606 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20230608 DATE AS OF CHANGE: 20230608 FILER: COMPANY DATA: COMPANY CONFORMED NAME: vTv Therapeutics Inc. CENTRAL INDEX KEY: 0001641489 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473916571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37524 FILM NUMBER: 231002231 BUSINESS ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 BUSINESS PHONE: 336-841-0300 MAIL ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 FORMER COMPANY: FORMER CONFORMED NAME: VTV Therapeutics Inc. DATE OF NAME CHANGE: 20150506 8-K 1 vtvt-20230606.htm 8-K vtvt-20230606
FALSE0001641489NASDAQ00016414892023-06-062023-06-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported):  June 6, 2023
vTv Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-37524
47-3916571
(State or other jurisdiction
of incorporation)
(Commission File No.)
(IRS Employer
Identification No.)
3980 Premier Drive, Suite 310
High Point, NC 27265
(Address of principal executive offices)
(336) 841-0300
(Registrant’s telephone number, including area code)
NOT APPLICABLE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stock, par value $0.01 per shareVTVT
NASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨



Item 5.07    Submission of Matters to a Vote of Security Holders.
On June 6, 2023, vTv Therapeutics Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:

(1)Based on the following results of the voting, the Company’s stockholders elected the nominees listed below to the Company’s Board of Directors, each to serve for a term to expire at the Company’s 2024 annual meeting of stockholders or until their successors are duly elected and qualified:

Director Nominee
For
Withheld
Broker Non Votes
John A. Fry65,554,590245,54410,687,845
Chandresh Harjivan
65,530,597269,53710,687,845
Keith Harris
65,281,995518,13910,687,845
Jonathan Isaacsohn65,386,409413,72510,687,845
Hersh Kozlov64,477,5071,322,62710,687,845
Fahed Al Marzooqi65,413,332386,80210,687,845
Richard S. Nelson
65,280,700519,43410,687,845
Paul Sekhri65,539,487260,64710,687,845
Howard L. Weiner65,392,364407,77010,687,845
(2)The Company’s stockholders approved on a nonbinding advisory basis the compensation paid to the Company’s named executive officers based upon the following results of the voting:

For
AgainstAbstainBroker Non Votes

64,740,672911,509147,95310,687,845
(3)The Company’s stockholders set the frequency of future nonbinding advisory votes on the compensation paid to the Company’s named executive officers as every three years based upon the following results of the voting:

1 Year
2 Years3 YearsAbstainBroker Non Votes

2,342,432114,44263,036,155307,105.10,687,845

Based upon the results of the voting, and consistent with the recommendation of the Board of Directors with regard to this proposal as set forth in the proxy materials for the Annual Meeting, the Company intends to conduct a non-binding advisory vote on the compensation of its named executive officers every three years until the next required vote regarding the frequency of advisory votes regarding the compensation of the company's named executive officers.
(4)The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified based on the following results of the voting:

For
AgainstAbstainBroker Non Votes

75,554,888895,65737,4340




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
VTV THERAPEUTICS INC.
By:/s/ Paul J. Sekhri
Name:Paul J. Sekhri
Title:President and Chief Executive Officer
Dated: June 8, 2023

EX-101.SCH 2 vtvt-20230606.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 vtvt-20230606_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 4 vtvt-20230606_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Jun. 06, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 06, 2023
Entity Registrant Name vTv Therapeutics Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37524
Entity Tax Identification Number 47-3916571
Entity Address, Address Line One 3980 Premier Drive, Suite 310
Entity Address, City or Town High Point
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27265
City Area Code 336
Local Phone Number 841-0300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, par value $0.01 per share
Trading Symbol VTVT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001641489
XML 6 vtvt-20230606_htm.xml IDEA: XBRL DOCUMENT 0001641489 2023-06-06 2023-06-06 false 0001641489 NASDAQ 8-K 2023-06-06 vTv Therapeutics Inc. DE 001-37524 47-3916571 3980 Premier Drive, Suite 310 High Point NC 27265 336 841-0300 false false false false Class A common stock, par value $0.01 per share VTVT NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://vtvtherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - vtvt-20230606.htm 4 vtvt-20230606.htm vtvt-20230606.xsd vtvt-20230606_lab.xml vtvt-20230606_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vtvt-20230606.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "vtvt-20230606.htm" ] }, "labelLink": { "local": [ "vtvt-20230606_lab.xml" ] }, "presentationLink": { "local": [ "vtvt-20230606_pre.xml" ] }, "schema": { "local": [ "vtvt-20230606.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vtvt", "nsuri": "http://vtvtherapeutics.com/20230606", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20230606.htm", "contextRef": "i9ccd7093213441849bf10cf8766b2b33_D20230606-20230606", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://vtvtherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtvt-20230606.htm", "contextRef": "i9ccd7093213441849bf10cf8766b2b33_D20230606-20230606", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001641489-23-000024-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001641489-23-000024-xbrl.zip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end